Bank of America
CYT

Bank of America’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Bank of America’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-89,304
Closed -$271K – 8338
2023
Q4 		$271K Buy
89,304
+8,830
+11% +$26.8K ﹤0.01% 5898
2023
Q3 		$229K Hold
80,474
– – ﹤0.01% 5834
2023
Q2 		$209K Buy
80,474
+12,935
+19% +$27.1K ﹤0.01% 5796
2023
Q1 		$123K Buy
67,539
+42,722
+172% +$69.4K ﹤0.01% 6168
2022
Q4 		$40.9K Buy
24,817
+3,810
+18% +$6.11K ﹤0.01% 6542
2022
Q3 		$40K Sell
21,007
-5,361
-20% -$14K ﹤0.01% 6773
2022
Q2 		$79K Buy
26,368
+2,138
+9% +$5.46K ﹤0.01% 6601
2022
Q1 		$92K Buy
24,230
+8,886
+58% +$50.6K ﹤0.01% 6912
2021
Q4 		$175K Buy
15,344
+3,016
+24% +$46K ﹤0.01% 6569
2021
Q3 		$216K Buy
12,328
+12,318
+123,180% +$230K ﹤0.01% 6258
2021
Q2 		$0 Buy
+10
New +$187 ﹤0.01% 8199

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Bank of America's CYT Position: Q1 2024 in Review

Bank of America sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 89,304 shares — an estimated $271K sold.

Bank of America first reported a position in CYT in Q2 2021 and held it in 11 quarters. The position peaked at $271K in Q4 2023. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Bank of America reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Bank of America sold 89,304 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $271K.
  • Bank of America first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
  • Bank of America's Cyteir Therapeutics, Inc. Common Stock position peaked at $271K in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Bank of America's 13F filing for Q1 2024, filed 15 May 2024.